Our purpose, strategy and culture

Vaccines help protect people from infectious diseases at every stage of life. Our vaccines portfolio is the broadest in the industry, helping protect people from meningitis, shingles, flu, polio, measles and many more. Today, two million doses of our vaccines are administered daily, and 4 in 10 of the world’s children receive a GSK jab each year. We use diverse platform technologies from adjuvants that improve vaccine effectiveness through to mRNA technology. These are at the heart of our pipeline differentiation.

Belgium is home to the core of GSK's Vaccines division, with three major production sites in Wavre, Rixensart and Gembloux, as well as the international operations centre 'GSK Vaccines'. This represents the largest industrial network for vaccine production in the world.

Specialty products are prescribed by healthcare professionals in so-called specialty therapeutic areas. For GSK, these include products in the areas of infectious diseases and severe asthma. In addition, we offer life-changing cancer drugs. In addition, we offer medicines for immune diseases, including the first new medicine in 50 years for lupus, a chronic autoimmune disease from which more than 4000 Belgian patients suffer.

We are global leaders in developing medicines for HIV. Having pioneered the first HIV treatments in the 1980s, our goal now is to limit the impact of HIV on people’s lives by treating, preventing and ultimately curing it.

First-line medicines are generally prescribed by general practitioners. At GSK, these include inhaled medicines for asthma and COPD, antibiotics and medicines for skin diseases. Every day, these medicines improve the health and lives of millions of people around the world. For more than 50 years, we have been helping millions of people with respiratory conditions to breathe easier, including the first inhalers in 1969. GSK in Belgium, with its portfolio of respiratory treatments, remains the industry leader.